Biopharma Quarterly Dealmaking Statistics, Q1 2016
A look at financing, M&A and alliance activity January–March 2016
Executive Summary
Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.
You may also be interested in...
Deals In Depth: June 2021
Six $1bn+ alliances were penned in June. Topping the list was Eisai’s potential $3.1bn collaboration Bristol-Myers Squibb for the co-development and co-commercialization of Eisai’s antibody drug conjugate MORAb-202 in Japan, China, select countries in the Asia-Pacific region, the US, Canada, Europe (including the EU and UK), and Russia. The candidate is in Phase I in Japan and Phase I/II in the US for anti-folate receptor alpha-positive solid tumors.
Seven Key Success Factors In Market Opportunity Assessments
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Deals In Depth: May 2021
Four $1b+ alliances were penned in May. Topping the list was Bristol-Myers Squibb’s deal with Agenus under which BMS will be granted a global exclusive license to the late-preclinical antibody program AGEN1777 along with a second undisclosed target. Agenus received a $200m up-front payment and could get up to $1.36bn in development, regulatory, and commercialization milestones, plus tiered royalties in the low double-digit to mid-teen range.